Biotech Values

[caravon]

Unfortunately, DNDN data did not demonstrate actual survival.

I carefully reviewed DNDN data. The data is very weak. By approving DNDN's drug, FDA will undermine the drug approval process supposedly based on integrity and soundness of clinical data rather than on someone guesses or speculations.

Such FDA action will be doing great disservice to cancer patients offering them unsubstantiated hopes.